Creative Medical Technology

CELZ

Market cap $6.81M

Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile Data Show Strong Functional and Pain Improvements Supported by Excellent Safety Profile

PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company advancing regenerative medicine and AI-enabled biodefense solutions, today announced that its BioDefense Inc. Burn Pit Initiative has received regulatory approval to proceed, marking a significant milestone in the Company's mission to address the long-term health consequences of toxic burn pit exposure among U.S. military veterans.

Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain Completion of Enrollment Positions CELZ for Near-Term Data Catalysts and Accelerates Path Toward Commercialization of a Transformative, Non-Opioid Therapy for Chronic Lower Back Pain

Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel's advancement across large unmet-need global markets

Creative Medical Technology Holdings, Inc. (CELZ) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform Selects Greenstone Biosciences to Accelerate AI-Driven iPSC Precision Medicine Platform

PHOENIX, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc., (Nasdaq: CELZ) (the “Company”), a clinical-stage biotechnology company pioneering regenerative immunotherapy, today announced that it has entered into agreements with certain holders of its existing warrants for the immediate exercise of outstanding warrants to purchase up to an aggregate of 1,116,136 shares of common stock of the Company originally issued in March 2025, at their current exercise price of $3.75 per share. The shares of common stock issuable upon exercise of the existing warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026 Ongoing Phase II Clinical Trials, Recently Issued Patents, and AI Integration Initiatives Set the Stage for Continuing Progress in 2026

Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical's Similar Research Focus Recent Issuance of U.S. Patents Covering ImmCelz™ — Supercharged Regulatory T Cell Programs in Heart Failure and Type 1 Diabetes Reinforce Creative Medical's Similar Research Focus

CELZ, GRFS and WHR have been added to the Zacks Rank #5 (Strong Sell) List on July 31, 2025.